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1.0   INTRODUCTION 
The human brain is made up of billions of neurons and 
glial cells which are interconnected and organized into 
specific patterns of neural circuitry, and hence is 
arguably the most sophisticated organ in human, both 
structurally and functionally. Studying the underlying 
mechanisms responsible for neurological or 
neurodegenerative disorders and the developmental 
basis of complex brain diseases such as autism, 
schizophrenia, bipolar disorder, Alzheimer’s and 
Parkinson’s disease has proven challenging due to 
practical and ethical limitations on experiments with 
human material and the limitations of existing 
biological/animal models. Recently, cerebral organoids 
have been proposed as a promising and revolutionary 
model for understanding complex brain disorders and 
preclinical drug screening.   
Cerebral organoids are in vitro-derived structures that 
resemble broad regional identities of the brain that 
recapitulate key features during brain development [1]. 
Various methods for neural culture have been published 
[2]. From embryoid body-derived neural rosette culture 
[3] to serum free floating culture of embryoid body-like 
aggregates approaches [4,5], the Lancaster protocol [6] 
is probably one of the most widely used methods to 
culture cerebral organoids. To more accurately mimic 
the complexity of the human brain, human embryonic 
stem cell lines (hESCs) and induced pluripotent stem 
cells (iPSCs) have been used to establish miniature 
replicas of human brain.  These cells can self-organize 
into complex structures, which model both proper 3D 
organization and the normal development of multiple 
brain regions. This model also recapitulates normal  
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Figure 1. Timeline of human brain and cerebral organoid development and their similarity throughout development 
(this figure is reproduced without any modifications from Kelava and Lancaster, 2016 [7] under the open access 
terms and creative common license CC BY 4.0, ). 
 
 
brain development on a gene expression, cellular and 
biological level, exhibiting almost all the major 
functional and neuroanatomical structures found in a 
developing fetal brain (Figure 1) [7]. 
 
2.0   CHALLENGES FACING CEREBRAL ORGANOIDS AS 
A MODEL 
Cerebral organoids have become increasingly popular 
as models to study various neurological, 
neurodegenerative and neuropsychiatric disorders. 
Despite their superiority in mimicking key aspects of 
physiological brain development and function, various 
challenges remain unresolved. 
 
• Random positioning of the developing brain 
structures  
Cerebral organoids develop in the absence of extra-
embryonic tissues that provide essential cues to set 
up the antero-posterior axis of the embryonic brain. 
As a result, cerebral organoids lack normal [8] 
embryonic axis formation, an important mechanism 
that instructs the ordered formation of specific 
brain regions in the correct orientation.  
 
 
 
• Cerebral organoids are not vascularized 
The lack of vascularization imposes constraints on 
the growth and development of organoids. Cerebral 
organoids often contain a necrotic core of cells that 
fail to survive in the absence of a blood supply. The 
absence of vascularization also currently precludes 
the use of organoids to study brain disorders that 
specifically involve the circulation, such as stroke. At 
rest, the richly vascularized adult brain receives 
approximately 15-20% of cardiac output. The 
absence of a vascular network in current cerebral 
organoids limits their application in the study of 
angiogenesis and cerebrovascular diseases. Current 
approaches to vascularize organoids including 
transplantation into mouse brain [9] and co-culture 
of neural cells with endothelial cells [8]. With recent 
development of engineered 3D vascular and 
neuronal networks [10], scientists can grow 
cerebral organoids directly on a microfluidic chip 
platform with combination of the relevant signaling 
molecules to enable proper patterning [11]. 
Vascularized organoids may be helpful for studying 
tumors as the vasculature is needed for growth of 
cancerous cells and facilitates metastasis.  
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• Organoids lack a blood-brain barrier (BBB) 
Although some aspects of a normal vascular 
network could be mimicked in a microfluidic 
platform, this could probably not be used to study 
the BBB. Attempts to reproduce the BBB in 
organoids include the co-culture of  a single layer of 
brain microvascular endothelial cells together with  
pericytes and astrocytes  [8]. The presence of a 
realistic BBB in cerebral organoids would make the 
model valuable for studying drug delivery and 
safety. Despite the success in mimicking BBB in 
various mixed cultures, the difficulty in modulating 
the tightness of BBB junctions and trans endothelial 
electrical resistance may stand in the way of making 
the system fully functional [12].  
 
• Difficult to orchestrate the development, support 
and function of glia architecture 
Glial architectural is essential to support the 
microenvironment of the CNS. The glial network 
includes microglia (resident innate immune cells 
derived from the mesoderm), astrocytes and 
oligodendrocytes (also known as neuroglia and 
derived from the ectoderm). They play crucial roles 
in the development and function of the brain and 
have been linked to various neurodevelopmental 
and neurodegenerative disorders [13,14]. The 
colonization timepoints of microglia, astrocytes and 
oligodendrocytes at different brain regions during 
neurodevelopment vary. The random positioning of 
different brain regions in cerebral organoids makes 
it difficult to recapitulate timely glial cell 
colonization and normal neuron-glia interaction in 
cerebral organoids. Despite these limitations, it was 
recently reported that microglia can also be innately 
derived from mesodermal cells within early stage 
cerebral organoids. The glia exhibited typical 
morphology, molecular profile, behavior and 
function of  microglia in vivo [15]. 
 
• Cellular heterogeneity and technical variability 
affect the consistency of cerebral organoids 
Different methods of culturing cerebral organoids 
and technical variability influence the cellular 
diversity and morphology of organoids, potentially 
affecting phenotypes of interest. Seeding different 
numbers of cells, timing of embedding, variations in 
genetic background and use of incompletely-
defined materials (such as Matrigel)  significantly 
affect the efficiency of embryoid body formation, 
their size, cellular diversity and gene expression 
thus making batch-to-batch experimental variations 
hard to control [16,17]. 
 
• Technical challenges in long-term culture 
Putting all the challenges above together, modeling 
neurodegenerative diseases that require long-term 
cultivation (from 9 months to years) of cerebral 
organoids is a very challenging task. As depicted in 
Figure 1, the transcriptome signatures of cerebral 
organoids are comparable to those of human brain 
during early development but not after second 
trimester. To model diseases in the adult or aging 
brain, long-term cerebral organoid culture is 
necessary. However, cerebral organoids are limited 
in their growth potential, due to the limited 
supporting scaffold and inaccessibility of cells within 
the organoids to the relevant nutrients leading to 
hypoxic or suboptimal growth conditions. To 
overcome this challenge, 3D printing of biomaterial 
scaffolds that couple with an artificial vascular 
network as well as microfluidic platforms may 
eventually enable much longer-term cerebral 
organoid cultivation. 
 
3.0   FUTURE PERSPECTIVE OF PRECISION MEDICINE 
USING CEREBRAL ORGANOIDS 
Despite the unresolved challenges, the limitations of 2D 
and genetically engineered mouse models highlight the 
tremendous potential of cerebral organoids in cancer 
therapy, neurodevelopmental diseases, 
neurodegenerative diseases and personalized medicine. 
Development of in vitro human cerebral organoids has 
offered new alternative avenues for disease modeling 
directly in human brain cells. Encouragingly, organoid 
technology together with advanced CRISPR-Cas9 gene-
editing approach have successfully initiated 
tumorigenesis in cerebral organoids [18,19].    
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Figure 2. Schematic representation of 3D culture technology in generating cerebral organoids from patient-derived 
hES/iPS cells for precision medicine. The cerebral organoids can be generated in large scale and cultured in 
microfluidic chip, further subject for drug screening, eventually leading to personalized therapeutic approaches.  
   
 
These models exhibit key features of cancer, such as 
cancer phenotypes, oncogenic-pathway-specific 
transcriptome profiles, and the potential for in vivo 
expansion and invasion.   
 
Now, researchers are on the move to develop patient-
specific organoids from a person’s own stem cells, 
paving ways towards precision medicine [6]. In patient-
derived organoids, patient’s own immune cells can be 
incorporated to facilitate the study of immunotherapies 
or immune responses related to host-pathogen 
interactions. Such studies are difficult when patient’s 
immune cells recognize generic organoids as foreign. In 
contrary, patient’s immune cells will recognize the 
organoids of the same origin as self without the risk of 
rejection. This will lead to a huge prospect to model and 
study immune responses during host-pathogen 
interactions and susceptibility [20], and cancer 
development [21].  
 
Conventionally, most patients with cancer receive 
similar “one-size-fits-all” treatment. It has recently 
become clear that certain treatments work well for 
some patients but do not show promising results in 
others. Individualized cancer treatments are 
progressively improving, and the trend has shifted 
towards “one dose, one patient” treatment. 
Personalized medicine means that clinicians and 
researchers need to obtain cells from a patient, grow 
brain organoids on a high throughout scale and test the 
effectiveness of a large set of drugs, finding the most 
appropriate for the patient (Figure 2). Personalized 
organoids which are directly derived from the patient, 
carry similar characteristics to the original tumors.  
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Together with drug-testing, it may result in more 
accurate prediction of drug response in patients and 
ultimately, represent an effective clinical usage of the 
organoid method [22].  
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